Welcome to Prism!

Upload scholarly work, create communities, get citable links and more. To get the most out of Prism, log in with your NetID and check out our guide.

Published August 2021 | Version v1.0.0
Journal Article Open

Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals.

Abstract

Background: Recent reports have suggested that among individuals previously infected with SARS-CoV-2, a single mRNA vaccine dose is sufficient to elicit high levels of immunity. Methods: We compared anti-SARS-CoV-2 spike receptor binding domain (RBD) IgG antibody concentrations and antibody-mediated neutralization of spike-angiotensin-converting enzyme (ACE2) receptor binding in vitro following vaccination of non-hospitalized participants by sero-status and acute virus diagnosis history. Participants were analysed before and after mRNA vaccination (BNT162b2/Pfizer or mRNA-1273/Moderna) in a community-based, home-collected, longitudinal serosurvey in the Chicago area (USA); none reported hospitalization for COVID-19. Samples were collected in January and February 2021. Before vaccination, some reported prior positive acute viral diagnostic testing and were seropositive (COVID-19+); the others who did not report acute viral diagnostic testing were categorized as seropositive or seronegative based on anti-spike RBD IgG test results. Findings: Of 307 unique vaccine recipients, 46 reported a prior COVID-19 diagnosis and were seropositive (COVID-19 +). Of the 261 with no history of acute viral diagnostic testing, 117 were seropositive and 144 seronegative before vaccination. The median age was 38 years (range 21-83) with 67 female and 33% male; 40% were non-White. Responses were evaluated after one (n = 142) or two (n = 191) doses of BNT162b2 or mRNA-1273 vaccine. After one dose, median post-vaccine IgG concentration and percent surrogate neutralization were each significantly higher among the COVID-19+ (median 48.2 mu g/ml, IgG; > 99.9% neutralization) compared to the seropositives (3.6 mu g/ml IgG; 56.5% neutralization) and seronegatives (2.6 mu g/ml IgG; 38.3% neutralization). The latter two groups reached > 95% neutralization after the second vaccine dose. Interpretation: After one dose of mRNA vaccine, individuals previously diagnosed with COVID-19 responded with high levels of anti-RBD IgG and surrogate neutralization of spike-ACE2 interaction. One dose of mRNA vaccine was not sufficient to generate comparably high responses among most persons previously infected with SARS-CoV-2 without a clinical COVID-19 diagnosis, nor among seronegative persons. (C) 2021 The Authors. Published by Elsevier Ltd.

Other

original_citation: Demonbreun AR, Sancilio A, Velez MP, Ryan DT, Saber R, Vaught LA, Reiser NL, Hsieh RR, D'Aquila RT, Mustanski B, McNally EM, McDade TW. Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals. Eclinicalmedicine. 2021;38:7.

Files

1-s2.0-S2589537021002984-main.pdf

Files (817.8 kB)

Name Size Download all
md5:23898a455ffacb4f3446ac1c0a9042de
817.8 kB Preview Download

Additional details

Identifiers

Funding

RAPID: Next phase serological testing for SARS-CoV-2 for biocultural research 2035114
National Science Foundation
Northwestern University Clinical and Translational Science Institute (NUCATS) 3UL1TR001422-06S4
National Center for Advancing Translational Sciences (NCATS)
Northwestern University

Dates

Created
2021-08
When the item was originally created.